Subramani R, Estrada A, Dixon M, Parada M, Rodriguez S, Pedroza D
Cancers (Basel). 2021; 13(13).
PMID: 34206988
PMC: 8267621.
DOI: 10.3390/cancers13133207.
Qian Y, Basu R, Mathes S, Arnett N, Duran-Ortiz S, Funk K
Cancers (Basel). 2020; 12(12).
PMID: 33291663
PMC: 7761932.
DOI: 10.3390/cancers12123640.
Yue Y, Jin C, Chen M, Zhang L, Liu X, Ma W
In Vitro Cell Dev Biol Anim. 2017; 53(8):699-705.
PMID: 28726188
DOI: 10.1007/s11626-017-0180-z.
Lee S, Kelleher S
Am J Physiol Endocrinol Metab. 2016; 311(2):E405-22.
PMID: 27354238
PMC: 5005964.
DOI: 10.1152/ajpendo.00495.2015.
Yuen K, Heaney A, Popovic V
Endocrine. 2016; 52(2):194-205.
PMID: 26732039
DOI: 10.1007/s12020-015-0840-2.
Obesity alters gene expression for GH/IGF-I axis in mouse mammary fat pads: differential role of cortistatin and somatostatin.
Villa-Osaba A, Gahete M, Cordoba-Chacon J, De Lecea L, Pozo-Salas A, Delgado-Lista F
PLoS One. 2015; 10(3):e0120955.
PMID: 25806796
PMC: 4373840.
DOI: 10.1371/journal.pone.0120955.
DNA methylation transcriptionally regulates the putative tumor cell growth suppressor ZNF677 in non-small cell lung cancers.
Heller G, Altenberger C, Schmid B, Marhold M, Tomasich E, Ziegler B
Oncotarget. 2014; 6(1):394-408.
PMID: 25504438
PMC: 4381603.
DOI: 10.18632/oncotarget.2697.
Immunoassay and Nb2 lymphoma bioassay prolactin levels and mammographic density in premenopausal and postmenopausal women the Nurses' Health Studies.
Rice M, Tworoger S, Bertrand K, Hankinson S, Rosner B, Feeney Y
Breast Cancer Res Treat. 2014; 149(1):245-53.
PMID: 25503962
PMC: 4381437.
DOI: 10.1007/s10549-014-3232-z.
Elevated GH/IGF-I promotes mammary tumors in high-fat, but not low-fat, fed mice.
Gahete M, Cordoba-Chacon J, Lantvit D, Ortega-Salas R, Sanchez-Sanchez R, Perez-Jimenez F
Carcinogenesis. 2014; 35(11):2467-73.
PMID: 25085903
PMC: 4216054.
DOI: 10.1093/carcin/bgu161.
Increased thyroid cancer risk in acromegaly.
Dagdelen S, Cinar N, Erbas T
Pituitary. 2013; 17(4):299-306.
PMID: 23836362
DOI: 10.1007/s11102-013-0501-5.
Autocrine human growth hormone expression leads to resistance of MCF-7 cells to tamoxifen.
Mojarrad M, Momeny M, Mansuri F, Abdolazimi Y, Hajifaraj Tabrizi M, Ghaffari S
Med Oncol. 2009; 27(2):474-80.
PMID: 19472088
DOI: 10.1007/s12032-009-9237-5.
The role of endocrine insulin-like growth factor-I and insulin in breast cancer.
Lann D, LeRoith D
J Mammary Gland Biol Neoplasia. 2008; 13(4):371-9.
PMID: 19030972
DOI: 10.1007/s10911-008-9100-x.
Identification of growth hormone receptor in plexiform neurofibromas of patients with neurofibromatosis type 1.
Cunha K, Porto Barboza E, Fonseca E
Clinics (Sao Paulo). 2008; 63(1):39-42.
PMID: 18297205
PMC: 2664176.
DOI: 10.1590/s1807-59322008000100008.
The contribution of growth hormone to mammary neoplasia.
Perry J, Mohankumar K, Emerald B, Mertani H, Lobie P
J Mammary Gland Biol Neoplasia. 2008; 13(1):131-45.
PMID: 18253708
PMC: 2665193.
DOI: 10.1007/s10911-008-9070-z.
Acromegaly: re-thinking the cancer risk.
Loeper S, Ezzat S
Rev Endocr Metab Disord. 2007; 9(1):41-58.
PMID: 18157698
DOI: 10.1007/s11154-007-9063-z.
Insulin-like growth factor (IGF)-I obliterates the pregnancy-associated protection against mammary carcinogenesis in rats: evidence that IGF-I enhances cancer progression through estrogen receptor-alpha activation via the mitogen-activated protein....
Thordarson G, Slusher N, Leong H, Ochoa D, Rajkumar L, Guzman R
Breast Cancer Res. 2004; 6(4):R423-36.
PMID: 15217511
PMC: 468665.
DOI: 10.1186/bcr812.
Identification of growth hormone receptor in localised neurofibromas of patients with neurofibromatosis type 1.
Cunha K, Barboza E, Da Fonseca E
J Clin Pathol. 2003; 56(10):758-63.
PMID: 14514779
PMC: 1770079.
DOI: 10.1136/jcp.56.10.758.
Oncological complications of excess GH in acromegaly.
Webb S, Casanueva F, Wass J
Pituitary. 2003; 5(1):21-5.
PMID: 12638722
DOI: 10.1023/a:1022149300972.
Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study.
Helle S, Geisler J, Poulsen J, Hestdal K, Meadows K, Collins W
Br J Cancer. 1998; 78(1):14-20.
PMID: 9662244
PMC: 2062954.
DOI: 10.1038/bjc.1998.435.
Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up.
Bontenbal M, Foekens J, Lamberts S, de Jong F, van Putten W, Braun H
Br J Cancer. 1998; 77(1):115-22.
PMID: 9459155
PMC: 2151275.
DOI: 10.1038/bjc.1998.18.